---
layout: default
title: Mannitol
parent: 僅模型預測 (L5)
nav_order: 86
evidence_level: L5
indication_count: 10
---

# Mannitol
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

The txgnn-pipeline skill is focused on pipeline operations; the report format is fully defined in my system prompt. I'll now generate the report based on the Evidence Pack. Key data constraints noted:

- `predicted_indications`: empty — no TxGNN prediction available
- `original_indications`: empty
- `taiwan_regulatory`: not marketed, zero licenses
- All safety fields: no data
- MOA: not available

---

# Mannitol: Evaluation Pending — No TxGNN Repurposing Prediction Generated

## One-Sentence Summary

Mannitol (DB00742) is a well-established osmotic agent used clinically to reduce intracranial pressure, treat cerebral edema, and promote renal excretion — though no original indication is recorded in the current evidence pack.
The TxGNN pipeline did **not generate any predicted new indications** for this candidate in the current run.
With zero Taiwan-approved products and no supporting evidence retrieved, this candidate cannot be evaluated for repurposing at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in evidence pack |
| Predicted New Indication | None — no TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (no predictions, no supporting studies) |
| Taiwan Market Status | Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

The TxGNN model did not produce any repurposing candidates for Mannitol in this evidence pack run. Without a predicted target indication, a mechanistic rationale for repurposing cannot be constructed.

From general clinical knowledge, Mannitol is a sugar alcohol that acts as an osmotic diuretic. It draws water from tissues into the vascular compartment via osmotic gradient, lowers intracranial and intraocular pressure, and supports renal excretion of toxic substances. Its primary pharmacological action is physical-osmotic rather than receptor-mediated or enzyme-targeted — a profile that may explain limited TxGNN signal in a graph-based prediction model oriented toward molecular interactions.

Currently, detailed mechanism of action data is not available in this evidence pack. Before repurposing analysis can proceed, TxGNN prediction data must be regenerated with complete DrugBank MOA inputs, and the TFDA package insert PDF must be retrieved and parsed to populate safety fields.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN predicted indications were generated for Mannitol, and there are zero Taiwan-approved products on record. Without a target indication, a repurposing evaluation cannot be conducted.

**To proceed, the following is needed:**

- Re-run the TxGNN prediction pipeline for Mannitol (DB00742) after confirming DrugBank molecular graph data is correctly loaded
- Retrieve MOA data from DrugBank API (remediation for DG002)
- Download and parse the TFDA package insert PDF to populate warnings and contraindications (remediation for DG001)
- Investigate why `original_indications` is empty — confirm whether this reflects a true regulatory gap or a data extraction issue
- Verify whether Mannitol's osmotic (non-receptor) mechanism reduces its graph-embedding similarity to disease nodes in the TxGNN knowledge graph, and consider supplementing with pathway-based features if appropriate
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

